MX2017007634A - Métodos para producir polipéptidos modificados por ctp de acción prolongada. - Google Patents

Métodos para producir polipéptidos modificados por ctp de acción prolongada.

Info

Publication number
MX2017007634A
MX2017007634A MX2017007634A MX2017007634A MX2017007634A MX 2017007634 A MX2017007634 A MX 2017007634A MX 2017007634 A MX2017007634 A MX 2017007634A MX 2017007634 A MX2017007634 A MX 2017007634A MX 2017007634 A MX2017007634 A MX 2017007634A
Authority
MX
Mexico
Prior art keywords
interest
ctp
modified polypeptide
clones
solution
Prior art date
Application number
MX2017007634A
Other languages
English (en)
Inventor
Hershkovitz Oren
Moschcovich Laura
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of MX2017007634A publication Critical patent/MX2017007634A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0633—Workflow analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0637—Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0639—Performance analysis of employees; Performance analysis of enterprise or organisation operations
    • G06Q10/06393—Score-carding, benchmarking or key performance indicator [KPI] analysis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0201—Market modelling; Market analysis; Collecting market data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Human Resources & Organizations (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Strategic Management (AREA)
  • Biotechnology (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Economics (AREA)
  • Development Economics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Educational Administration (AREA)
  • General Business, Economics & Management (AREA)
  • Game Theory and Decision Science (AREA)
  • Marketing (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Finance (AREA)
  • Accounting & Taxation (AREA)
  • Operations Research (AREA)
  • Quality & Reliability (AREA)

Abstract

Se describe en la presente un método para fabricar un polipéptido de interés recombinante modificado por una extensión de CTP en un sistema de cultivo de células de mamífero.
MX2017007634A 2014-12-10 2015-12-10 Métodos para producir polipéptidos modificados por ctp de acción prolongada. MX2017007634A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462090116P 2014-12-10 2014-12-10
US201462090124P 2014-12-10 2014-12-10
US201462090104P 2014-12-10 2014-12-10
PCT/IL2015/051197 WO2016092550A2 (en) 2014-12-10 2015-12-10 Methods of producing long acting ctp-modified polypeptides

Publications (1)

Publication Number Publication Date
MX2017007634A true MX2017007634A (es) 2017-08-28

Family

ID=56106835

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017007634A MX2017007634A (es) 2014-12-10 2015-12-10 Métodos para producir polipéptidos modificados por ctp de acción prolongada.
MX2017007635A MX2017007635A (es) 2014-12-10 2015-12-10 Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017007635A MX2017007635A (es) 2014-12-10 2015-12-10 Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada.

Country Status (22)

Country Link
US (3) US20180111974A1 (es)
EP (4) EP4253407A3 (es)
KR (3) KR20200118505A (es)
CN (1) CN107438623B (es)
AU (2) AU2015358890B2 (es)
CO (1) CO2017006870A2 (es)
EA (1) EA201791275A1 (es)
ES (1) ES2943359T3 (es)
HK (2) HK1243444A1 (es)
HR (1) HRP20230405T8 (es)
IL (2) IL252788B (es)
MX (2) MX2017007634A (es)
NZ (1) NZ733113A (es)
PE (1) PE20171380A1 (es)
PH (1) PH12017501089A1 (es)
PL (1) PL3230309T3 (es)
RU (2) RU2021103436A (es)
SG (1) SG11201704706RA (es)
SI (1) SI3230309T1 (es)
TW (2) TW202231657A (es)
WO (2) WO2016092549A1 (es)
ZA (1) ZA201704595B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
PE20171380A1 (es) 2014-12-10 2017-09-15 Opko Biologics Ltd Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada
ES2893616T3 (es) 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
SG10202100189WA (en) * 2016-07-11 2021-02-25 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
RU2652884C1 (ru) * 2016-11-25 2018-05-03 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Штамм клеток яичников китайского хомячка сно-еро 4а9 - продуцент высокосиалированного эритропоэтина
US20200262887A1 (en) * 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
US20210008172A1 (en) * 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions
EP4308151A1 (en) * 2021-03-19 2024-01-24 Pfizer Inc. Methods of administering long-acting growth hormone polypeptides

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE68917883T2 (de) 1988-05-06 1995-02-23 Toray Industries Stabile interferon-beta-zusammensetzung.
ATE148171T1 (de) 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
ATE109507T1 (de) * 1989-04-28 1994-08-15 Miles Inc Grossfermenter-inokulation mit gefrorenen zellen.
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
PT695307E (pt) * 1993-04-20 2000-05-31 Univ Washington Farmacos de proteinas e peptidos modificados
WO1995035116A1 (en) * 1994-06-17 1995-12-28 Applied Research Systems Hgh containing pharmaceutical compositions
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
CN1847265A (zh) * 2005-04-15 2006-10-18 上海市计划生育科学研究所 人绒毛膜促性腺激素β链羧基端37肽多聚体及用途
WO2007092252A2 (en) 2006-02-03 2007-08-16 Modigene Inc Long-acting polypeptides and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9249407B2 (en) * 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
SG189872A1 (en) * 2010-10-11 2013-06-28 Abbvie Inc Processes for purification of proteins
EP3791890A1 (en) 2012-02-14 2021-03-17 OPKO Biologics Ltd. Long-acting coagulation factors and uses thereof
WO2013152351A2 (en) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
WO2013157002A1 (en) 2012-04-19 2013-10-24 Prolor Biotech Inc. Long-acting oxyntomodulin variants and methods of producing same
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
KR102202255B1 (ko) * 2012-11-20 2021-01-13 옵코 바이오로직스 리미티드 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법
US11045523B2 (en) * 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
PE20171380A1 (es) 2014-12-10 2017-09-15 Opko Biologics Ltd Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada
ES2893616T3 (es) * 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos

Also Published As

Publication number Publication date
EP3240564A4 (en) 2018-05-30
SG11201704706RA (en) 2017-07-28
ZA201704595B (en) 2019-06-26
US20210371487A1 (en) 2021-12-02
TW202231657A (zh) 2022-08-16
EP3230309A1 (en) 2017-10-18
HRP20230405T8 (hr) 2023-09-29
US20160168588A1 (en) 2016-06-16
EP4253407A3 (en) 2023-12-06
CN107438623A (zh) 2017-12-05
EP3240564A2 (en) 2017-11-08
EP4212546A1 (en) 2023-07-19
RU2017123789A (ru) 2019-01-10
AU2019203609A1 (en) 2019-06-13
KR20220058564A (ko) 2022-05-09
TW201638105A (zh) 2016-11-01
AU2015358890A1 (en) 2017-07-20
PL3230309T3 (pl) 2023-08-28
AU2019203609B2 (en) 2021-02-25
MX2017007635A (es) 2017-09-11
WO2016092549A1 (en) 2016-06-16
PH12017501089A1 (en) 2017-10-18
EA201791275A1 (ru) 2017-12-29
CO2017006870A2 (es) 2018-01-05
US20180111974A1 (en) 2018-04-26
AU2015358890B2 (en) 2019-06-13
WO2016092550A2 (en) 2016-06-16
SI3230309T1 (sl) 2023-08-31
TWI746427B (zh) 2021-11-21
KR102164352B1 (ko) 2020-10-13
HRP20230405T1 (hr) 2023-09-01
RU2017123789A3 (es) 2019-01-10
NZ733113A (en) 2020-09-25
IL252788A0 (en) 2017-08-31
ES2943359T3 (es) 2023-06-12
HK1246322A1 (zh) 2018-09-07
IL252778A0 (en) 2017-08-31
PE20171380A1 (es) 2017-09-15
KR20170086664A (ko) 2017-07-26
RU2743295C2 (ru) 2021-02-16
IL252788B (en) 2021-09-30
EP3230309B1 (en) 2023-03-29
RU2021103436A (ru) 2021-02-25
HK1243444A1 (zh) 2018-07-13
KR102527180B1 (ko) 2023-04-27
CN107438623B (zh) 2023-07-14
KR20200118505A (ko) 2020-10-15
BR112017012498A2 (pt) 2018-07-31
WO2016092550A3 (en) 2016-08-04
IL252778B (en) 2021-09-30
EP4253407A2 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
MX2017007634A (es) Métodos para producir polipéptidos modificados por ctp de acción prolongada.
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
MX2016004564A (es) Cultivo celular metabolicamente optimizado.
HRP20190970T1 (hr) Polipeptidi koji sadrže neglikozilirani fc
MX2019004499A (es) Sistemas de replicón de virus recombinante y usos de estos.
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
MX2010007729A (es) Vectores de expresion de mamifero mejorados y uso de los mismos.
MY172997A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
SG10201809146QA (en) Recombinant host cell engineered to overexpress helper proteins
JP2014524241A5 (es)
BR112016012229A2 (pt) métodos de produção de polipeptídeos
MX2010004397A (es) Celula para uso en la produccion de proteina exogena y proceso de produccion que utiliza la celula.
SG10201900915WA (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
MX2017011220A (es) Metodos para hacer celulas madre neurales y usos de las mismas.
RU2015129656A (ru) Гуманизированное моноклональное антитело, специфичное к синдекану-1
SV2017005545A (es) Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y metodos para usar los mismos
WO2013163654A3 (en) Nucleic acids, cells, and methods for producing secreted proteins
MX2020002903A (es) Método para potenciar la expresión de arn en una célula.
JP2017524366A5 (es)
MX2018015596A (es) Proteina de fusion entre el factor de viabilidad de los conos derivado de bastones de forma corta y un peptido hidrofilo.
AR102969A1 (es) Métodos para producir polipéptidos modificados por ctp (péptido carboxilo terminal) de acción prolongada
MX2022008298A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
WO2019088496A3 (ko) 내인성 폴리펩타이드 생산을 위한 재조합 세포 및 방법
WO2019038555A3 (en) TAT EXPRESSION SYSTEM